Drugs

, Volume 69, Issue 1, pp 51–69 | Cite as

Management of NSAID-Induced Gastrointestinal Toxicity

Focus on Proton Pump Inhibitors
Therapy in Practice

Abstract

The association between NSAIDs and the presence of upper gastrointestinal (GI) complications is well established. Evidence that acid aggravates NSAID-induced injury provides a rationale for minimizing such damage by acid suppression.

Proton pump inhibitors (PPIs) appear to be very effective in treating NSAID-related dyspepsia, and also in healing gastric and duodenal ulcers in patients continuing to receive the NSAID. An analysis of data from comparative studies of PPIs versus ranitidine, misoprostol and sucralfate shows a therapeutic advantage in favour of the PPI. Several studies now confirm the efficacy of co-therapy with PPIs in the short- and long-term prevention of NSAID-induced upper GI injury. PPIs are more effective than histamine H2-receptor antagonists at standard dosages in reducing the risk of gastric and duodenal ulcer, and are superior to misoprostol in preventing duodenal but not gastric lesions. However, when balancing effectiveness and tolerance, PPIs may be considered the treatment of choice in the short- and long-term prevention of NSAID-related mucosal lesions.

To date, there are only a few published articles dealing with the role of PPIs in the prevention of upper GI complications. Recent epidemiological and interventional studies provide some evidence that PPIs are of benefit. However, more controlled studies using clinical outcomes are needed to establish the best management strategy (PPIs combined with traditional NSAIDs or with cyclo-oxygenase-2 selective inhibitors) especially in patients with multiple risk factors, in patients using concomitant low-dose aspirin, corticosteroids or anticoagulants (high risk group), or in patients with a history of ulcer complications (very high risk group).

Furthermore, it should be underlined that Helicobacter pylori infection positively interacts with the gastroprotective effect of PPIs; therefore, the true efficacy of these drugs in preventing NSAID-related ulcer complications should be reassessed without the confounding influence of this microorganism.

References

  1. 1.
    Tseng C, Wolfe M. Non steroidal antiinflammatory drugs. Med Clin North Am 2000; 84: 1329–44PubMedCrossRefGoogle Scholar
  2. 2.
    MacDonald TM. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology (Oxford) 2000; 39 Suppl. 2: 13–20CrossRefGoogle Scholar
  3. 3.
    Kremer J. From prostaglandin replacement to specific COX-2 inhibition: a critical appraisal. J Rheumatol 2000; 27 Suppl. 60: 9–12Google Scholar
  4. 4.
    Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in partients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double blind placebo controlled trial. Ann Intern Med 1995; 123: 241–9PubMedGoogle Scholar
  5. 5.
    Ofman J, Maclean C, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002; 29: 804–12PubMedGoogle Scholar
  6. 6.
    Singh G, Triadafilopoulus G. Epidemiology of NSAID-induced GI complications. J Rheumatol 1999; 26: 18–24Google Scholar
  7. 7.
    Lanas A, Perez-Aisa MA, Feu F, et al. Nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with non-steroidal anti-inflammatory drug use. Am J Gastroenterol 2005; 100: 1685–93PubMedCrossRefGoogle Scholar
  8. 8.
    Cryer B. NSAID-associated death: the rise and fall of NSAID associated GI mortality. Am J Gastroenterol 2005; 100: 1694–5PubMedCrossRefGoogle Scholar
  9. 9.
    Henry D, McGettigan P. Selective Cox-2 inhibitors: a promise unfulfilled? Gastroenterology 2007; 132: 790–808PubMedCrossRefGoogle Scholar
  10. 10.
    García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007; 132: 498–506PubMedCrossRefGoogle Scholar
  11. 11.
    Scheiman JM. Prevention of NSAID-induced ulcers current treatment options. Gastroenterology 2008; 11: 125–34Google Scholar
  12. 12.
    Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008; 12(11): 1–278PubMedGoogle Scholar
  13. 13.
    Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113: 1950–7PubMedCrossRefGoogle Scholar
  14. 14.
    Howes LG. Selective COX-2 inhibitors, NSAIDs and cardiovascular events: is celecoxib the safest choice? Ther Clin Risk Manag 2007; 3: 831–45PubMedGoogle Scholar
  15. 15.
    Kearney PM, Baigent C, Godwin J, et al. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302–8PubMedCrossRefGoogle Scholar
  16. 16.
    Gabriel SE, Jaakkimainen L, Bomaberdier C. Risk for serious gastrointestinal complications related to use of non-steroidal antiinflammatory drugs: a meta analysis. Ann Intern Med 1991; 115: 787–96PubMedGoogle Scholar
  17. 17.
    Tamblyn R, Berkson L, Duaphinee WD, et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 1997; 127: 429–38PubMedGoogle Scholar
  18. 18.
    Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 377–88PubMedCrossRefGoogle Scholar
  19. 19.
    Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64: 669–81PubMedCrossRefGoogle Scholar
  20. 20.
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520–8PubMedCrossRefGoogle Scholar
  21. 21.
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–55PubMedCrossRefGoogle Scholar
  22. 22.
    Edwards JE, McQuay HJ, Moore RA. Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Pain 2004; 111: 286–96PubMedCrossRefGoogle Scholar
  23. 23.
    Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98: 1725–33PubMedCrossRefGoogle Scholar
  24. 24.
    Kivitz AJ, Nayiager S, Schimansky T, et al. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 2004; 19: 1189–98PubMedCrossRefGoogle Scholar
  25. 25.
    Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 288–92PubMedCrossRefGoogle Scholar
  26. 26.
    Dai C, Stafford RS, Alexander GC. National trends in cyclo-oxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005; 165: 171–7PubMedCrossRefGoogle Scholar
  27. 27.
    Mamdani M, Juurlink DN, Kopp A, et al. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 2004; 328: 1415–6PubMedCrossRefGoogle Scholar
  28. 28.
    Lanas A, Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 2006; 38: 415–28PubMedCrossRefGoogle Scholar
  29. 29.
    Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621–6PubMedCrossRefGoogle Scholar
  30. 30.
    Elliott SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996; 23: 432–4PubMedCrossRefGoogle Scholar
  31. 31.
    Rowe PH, Starlinger MJ, Kasdon E, et al. Parenteral aspirin and sodium salicylate are equally injurious to the rat gastric mucosa. Gastroenterology 1987; 93: 863–71PubMedGoogle Scholar
  32. 32.
    Shiotani A, Yamaoka Y, El-Zimaity HMT, et al. NSAID gastric ulceration: predictive value of gastric pH, mucosal density of polymorphonucleate leukocytes or levels of IL-8 or nitrite. Dig Dis Sci 2002; 47: 38–43PubMedCrossRefGoogle Scholar
  33. 33.
    Savarino V, Mela GS, Zentilin P, et al. Effect of one-month treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. Dig Dis Sci 1998; 43: 459–63PubMedCrossRefGoogle Scholar
  34. 34.
    Fledman M, Colturi TJ. Effect of indomethacin on gastric acid and bicarbonate secretions in humans. Gastroenterology 1984; 87: 1339–43Google Scholar
  35. 35.
    Scarpignato C, Pelosini I. Prevention and treatment of nonsteroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Ital J Gastroenterol Hepatol 1999; 31 Suppl. 1: S63–72PubMedGoogle Scholar
  36. 36.
    Wallace JL, McKnight GW. The mucoid cap over superficial gastric damage in the rat: a high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin. Gastroenterology 1990; 99: 295–304PubMedGoogle Scholar
  37. 37.
    Schmassmann A, Tarnawski A, Peskar BM, et al. Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats: interaction with indomethacin. Am J Physiol 1995; 268: G276–85PubMedGoogle Scholar
  38. 38.
    Green Jr FW, Kaplan MM, Curtis LE, et al. Effect of acid and pepsin on blood coagulation and platelet aggregation: a possible contributor to prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74: 38–43PubMedGoogle Scholar
  39. 39.
    Goldstein JL, Miner Jr PB, Schlesinger PK, et al. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2006; 23: 1189–96PubMedCrossRefGoogle Scholar
  40. 40.
    Blandizzi C, Natale G, Gherardi G, et al. Acid-independent gastroprotective effects of lansoprazole in experimental mucosal injury. Dig Dis Sci 1999; 44: 2039–50PubMedCrossRefGoogle Scholar
  41. 41.
    Tsuji S, Sun WH, Tsuji M, et al. Lansoprazole induces mucosal protection through gastrin receptor-dependent up-regulation of cyclooxygenase-2 in rats. J Pharmacol Exp Ther 2002; 303: 1301–8PubMedCrossRefGoogle Scholar
  42. 42.
    Wallace JL, Granger DN. The cellular and molecular basis of gastric mucosal defence. FASEB J 1996; 10: 731–40PubMedGoogle Scholar
  43. 43.
    Suzuki M, Mori M, Miura S, et al. Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med 1996; 21: 727–31PubMedCrossRefGoogle Scholar
  44. 44.
    Blandizzi C, Fornai M, Colucci R, et al. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol 2005; 11: 4052–60PubMedGoogle Scholar
  45. 45.
    Jaworski T, Sarosiek I, Sostarich S, et al. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci 2005; 50: 357–65PubMedCrossRefGoogle Scholar
  46. 46.
    Skoczylas T, Sarosiek I, Sostarich S, et al. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci 2003; 48: 322–8PubMedCrossRefGoogle Scholar
  47. 47.
    Wiklund I. Quality of life in arthritis patients using non-steroidal anti-inflammatory drugs. Can J Gastroenterol 1999; 13: 129–33PubMedGoogle Scholar
  48. 48.
    Jones RH, Tait CL. Gastrointestinal side-effects of NSAIDs in the community. Br J Clin Pract 1995; 49: 67–70PubMedGoogle Scholar
  49. 49.
    Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004; 127: 1038–43PubMedCrossRefGoogle Scholar
  50. 50.
    Bijlsma JW. Treatment of NSAID-induced gastrointestinal lesions with cimetidine: an international multicenter collaborative study. Aliment Pharmacol Ther 1988; 2: 85–95PubMedCrossRefGoogle Scholar
  51. 51.
    Van Groeneandael JHLM, Markusse HM, Dijkmans BAC, et al. The effect of ranitidine on NSAID-related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis or osteoarthritis. Clin Rheumatol 1996; 15: 450–6CrossRefGoogle Scholar
  52. 52.
    Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric an duodenal ulcers caused by non-steroidal antiinflammatory drugs. N Engl J Med 1996; 334: 1435–9PubMedCrossRefGoogle Scholar
  53. 53.
    Yeomans ND, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine Versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719–26PubMedCrossRefGoogle Scholar
  54. 54.
    Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727–34PubMedCrossRefGoogle Scholar
  55. 55.
    Hawkey C, Talley NJ, Yeomans ND, et al. NASA1 SPACE1 Study Group. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005; 100: 1028–36PubMedCrossRefGoogle Scholar
  56. 56.
    Hawkey CJ, Jones RH, Yeomans ND, et al. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2007; 25: 813–21PubMedCrossRefGoogle Scholar
  57. 57.
    LoJudice TA, Saleem T, Lang JA. Cimetidine in the treatment of gastric ulcer, induced by steroidal and non-steroidal anti-inflammatory agents. Am J Gastroenterol 1981; 75: 104–10Google Scholar
  58. 58.
    O’Laughlin JC, Silvoso GR, Ivey KJ. Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin. Dig Dis Sci 1982; 27: 976–80PubMedCrossRefGoogle Scholar
  59. 59.
    Davies J, Collins AJ, Dixon A. The influence of cimetidine on peptic ulcers patients with arthritis taking anti-inflammatory drugs. Br J Rheumathol 1986; 25: 54–8CrossRefGoogle Scholar
  60. 60.
    Roth SH, Bennet RE, Mitchell CS, et al. Cimetidine therapy in non-steroidal antiinflammatory drug gastropathy. Arch Int Med 1987; 147: 1798–801CrossRefGoogle Scholar
  61. 61.
    Wallin BA, Frank WO, Fox MJ, et al. The effects of cimetidine on the healing of non-steroidal antiinflammatory drug-induced gastroduodenal damage while continuing NSAID therapy [abstract]. Am J Gastroenterol 1988; 83: 1076Google Scholar
  62. 62.
    Bank S, Zucker S, Grenberg R, et al. Effect of famotidine on gastric ulcer healing: a comparison between nonsteroidal and aspirin induced ulceration and idiopathic ulcers [abstract]. Am J Gastroenterol 1991; 86: 1308Google Scholar
  63. 63.
    Wu CS, Wang SH, Chen PC, et al. Does famotidine have the similar efficacy to misoprostol in the treatment of non-steroidal anti-inflammatory drug-induced gastropathy? Int J Clin Pract 1998; 52: 472–4PubMedGoogle Scholar
  64. 64.
    Lancaster Smith MJ, Jadeberg ME, Jackson DA. Ranitidine in the treatment of non steroidal antiinflammatory drug associated gastric and duodenal ulcer. Gut 1991; 32: 252–5PubMedCrossRefGoogle Scholar
  65. 65.
    Ehsanullah RS, Page MC, Tildesley G, et al. A placebo-controlled study of ranitidine in healing NSAID-associated gastric and duodenal ulcers [abstract]. Br J Rheumatol 1990; 29 Suppl. 2: 9Google Scholar
  66. 66.
    Misra SP, Kumar N, Anand BS. Aspirin concurrently administered with ranitidine does not delay healing of duodenal ulcer. Aust NZ J Med 1990; 20: 201–3CrossRefGoogle Scholar
  67. 67.
    Walan A, Bader JP, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320: 69–75PubMedCrossRefGoogle Scholar
  68. 68.
    Bianchi Porro G, Lazzaroni M, Manzionna G, et al. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther 1998; 12: 355–60PubMedCrossRefGoogle Scholar
  69. 69.
    Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000; 160: 1455–61PubMedCrossRefGoogle Scholar
  70. 70.
    Campbell DR, Haber MM, Sheldon E, et al. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidalanti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol 2002; 97: 2208–14PubMedCrossRefGoogle Scholar
  71. 71.
    Olteanu D, Balan C, Andronescu A, et al. Efficacy of pantoprazole as compared to omeprazole and misoprostol in NSAID associated gastric ulcer [abstract]. Gut 2000; 47 Suppl. III: A82Google Scholar
  72. 72.
    Goldstein JL, Johanson JF, Suchower LJ, et al. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 2005; 100: 2650–7PubMedCrossRefGoogle Scholar
  73. 73.
    Goldstein JL, Johanson JF, Hawkey CJ, et al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy. A randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther 2007; 26: 1101–11PubMedCrossRefGoogle Scholar
  74. 74.
    Laheij RJ, Van Rossum LG, Jansen JB, et al. Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial. Aliment Pharmacol Ther 2003; 18: 109–15PubMedCrossRefGoogle Scholar
  75. 75.
    Bianchi Porro G, Lazzaroni M, Petrillo M, et al. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment: a double blind placebo controlled study. Ital J Gastroenterol Hepatol 1998; 30: 43–7PubMedGoogle Scholar
  76. 76.
    Daneshmend TK, Stein AG, Bhaskar NK, et al. Abolition by omeprazole of aspirin induced gastric injury in man. Gut 1990; 31: 514–7PubMedCrossRefGoogle Scholar
  77. 77.
    Scheiman JM, Behler EM, Loeffler KM, et al. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 1994; 39: 97–103PubMedCrossRefGoogle Scholar
  78. 78.
    Oddsson E, Gudjónsson H, Thjódleifsson B. Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen. Scand J Gastroenterol 1992; 27: 1045–8PubMedCrossRefGoogle Scholar
  79. 79.
    Simon B, Elsner H, Müller P. Protective effect of omeprazole against low-dose acetylsalicylic acid: endoscopic controlled double-blind study in healthy subjects [in German]. Arzneimittel Forschung 1995; 45: 701–3PubMedGoogle Scholar
  80. 80.
    Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002; 51: 329–35PubMedCrossRefGoogle Scholar
  81. 81.
    Bigard MA. Protective effect of omeprazole on gastric lesions induced by a single dose of aspirin in man. Gastroenterol Clin Biol 1988; 12: 770–1PubMedGoogle Scholar
  82. 82.
    Bergmann JF, Chassany O, Simoneau G, et al. Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses. Clin Pharmacol Ther 1992; 52: 413–6PubMedCrossRefGoogle Scholar
  83. 83.
    Müller P, Fuchs W, Simon B. Studies on the protective effect of lansoprazole on human gastric mucosa against low-dose acetylsalicylic acid: an endoscopic controlled double-blind study [in German]. Arzneimittel Forschung 1997; 47: 758–60PubMedGoogle Scholar
  84. 84.
    Irani S, Krevsky B, Desipio J, et al. Rapid protection of the gastroduodenal mucosa against aspirin-induced damage by rabeprazole. Aliment Pharmacol Ther 2008; 27: 498–503PubMedCrossRefGoogle Scholar
  85. 85.
    Pilotto A, Di Mario F, Franceschi M, et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. Aliment Pharmacol Ther 2000; 14: 1077–82PubMedCrossRefGoogle Scholar
  86. 86.
    Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20: 1091–7PubMedCrossRefGoogle Scholar
  87. 87.
    Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998; 12: 135–40PubMedCrossRefGoogle Scholar
  88. 88.
    Ekström P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multicentre study. Scand J Gastroenterol 1996; 31: 753–8PubMedCrossRefGoogle Scholar
  89. 89.
    Bianchi Porro G, Imbesi V, Lazzaroni M, et al. Efficacy of pantoprazole in the prevention of peptic ulcers induced by nonsteroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind: parallel-group study. Dig Liver Dis 2000; 32: 201–8PubMedCrossRefGoogle Scholar
  90. 90.
    James M, Scheiman MD, Neville D, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701–10CrossRefGoogle Scholar
  91. 91.
    Yeomans N, Scheiman JM, Hawkey CJ, et al. An evidence-based analysis of esomeprazole therapy versus placebo for the prevention of gastric or duodenal ulcers in at-risk continous NSAID users [abstract]. Gastroenterology 2004; 126 Suppl. 2: A–604Google Scholar
  92. 92.
    Miyake K, Ueki N, Suzuki K, et al. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. Aliment Pharmacol Ther 2005; 21 Suppl. 2: 67–72PubMedCrossRefGoogle Scholar
  93. 93.
    Stupnicki T, Dietrich K, González-Carro P, et al. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion 2003; 68: 198–208PubMedCrossRefGoogle Scholar
  94. 94.
    Graham DY, Agrawal NM, Campbell DR, et al. NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of miso-prostol vs lansoprazole. Arch Intern Med 2002; 162: 169–75PubMedCrossRefGoogle Scholar
  95. 95.
    Rostom A, Wells G, Tugwell P, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2000; (4): CD002296Google Scholar
  96. 96.
    Rostom A, Wells G, Tugwell P, et al. Prevention of chronic NSAID induced upper gastrointestinal toxicity. J Rheumatol 2000; 27: 2204–14Google Scholar
  97. 97.
    Leandro G, Pilotto A, Franceschi M, et al. Prevention of severe acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig Dis Sci 2001; 46: 1924–36PubMedCrossRefGoogle Scholar
  98. 98.
    Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; (4): CD002296Google Scholar
  99. 99.
    Brown TJ, Hooper L, Elliott RA, et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006; 10: 1–183Google Scholar
  100. 100.
    Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. Br Med J 2004; 329: 948–57CrossRefGoogle Scholar
  101. 101.
    Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose ASA or naproxen. N Engl J Med 2001; 344: 967–73PubMedCrossRefGoogle Scholar
  102. 102.
    Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033–8PubMedCrossRefGoogle Scholar
  103. 103.
    Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104–10PubMedCrossRefGoogle Scholar
  104. 104.
    Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005; 118: 1271–8PubMedCrossRefGoogle Scholar
  105. 105.
    Garcia Rodriguez LA, Ruigomez A. Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. Epidemiology 1999; 10: 228–32PubMedCrossRefGoogle Scholar
  106. 106.
    Fries JF, Murtagh KN, Bennett M, et al. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2433–40PubMedCrossRefGoogle Scholar
  107. 107.
    Lanas A, Rodrigo L, Márquez JL, et al. EMPHASYS Study Group. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDs and omeprazole. Scand J Gastroenterol 2003; 38: 693–700PubMedCrossRefGoogle Scholar
  108. 108.
    Ray WA, Chung CP, Stein CM, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology 2007; 133: 790–8PubMedCrossRefGoogle Scholar
  109. 109.
    Rahme E, Barkun AN, Toubouti Y, et al. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib? Arthritis Rheum 2007; 57: 748–55PubMedCrossRefGoogle Scholar
  110. 110.
    Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834–9PubMedCrossRefGoogle Scholar
  111. 111.
    Höer A, Gothe H, Schiffhorst G, et al. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease. Pharmacoepidemiol Drug Saf 2007; 16: 854–8PubMedCrossRefGoogle Scholar
  112. 112.
    Lanas A, García-Rodríguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, anti-platelet agents, and anticoagulants. Am J Gastroenterol 2007; 102: 507–15PubMedCrossRefGoogle Scholar
  113. 113.
    Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731–8PubMedCrossRefGoogle Scholar
  114. 114.
    Targownik LE, Metge CJ, Leung S, et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008; 134: 937–44PubMedCrossRefGoogle Scholar
  115. 115.
    Hawkey CJ, Lanas AI. Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement. Am J Med 2001; 110: 79–100SCrossRefGoogle Scholar
  116. 116.
    Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract 2005; 59: 1210–7PubMedCrossRefGoogle Scholar
  117. 117.
    Mel Wilcox C, Allison J, Benzuly K, et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 2006; 4: 1082–9PubMedCrossRefGoogle Scholar
  118. 118.
    Graham DY. Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users. Helicobacter 2002; 7: 1–8PubMedCrossRefGoogle Scholar
  119. 119.
    Chan FKL, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications. Review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004; 19: 1051–61PubMedCrossRefGoogle Scholar
  120. 120.
    Graham DY. Ulcer complications and their nonoperative treatment. In: Sleisenger MH, Fordtran JS, editors. Gastrointestinal disease: pathophysiology, diagnosis, management. 5th ed. Philadelphia (PA): WB Saunders Co, 1993: 698–712Google Scholar
  121. 121.
    Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: a randomized, controlled study. Ann Intern Med 1992; 116: 705–8PubMedGoogle Scholar
  122. 122.
    Graham DY, Hepps KS, Ramirez FC, et al. Treatment of H. pylori reduces the rate of rebleeding in complicated pepticulcer disease. Scand J Gastroenterol 1993; 28: 939–42PubMedCrossRefGoogle Scholar
  123. 123.
    Labenz J, Borsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994; 55: 19–23PubMedCrossRefGoogle Scholar
  124. 124.
    Gutierrez O, Melo M, Segura AM, et al. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997; 32: 664–8PubMedCrossRefGoogle Scholar
  125. 125.
    El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15–24PubMedCrossRefGoogle Scholar
  126. 126.
    Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725–32PubMedCrossRefGoogle Scholar
  127. 127.
    Goldstein JL, Howard KB, Walton SM, et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006; 11: 1337–45CrossRefGoogle Scholar
  128. 128.
    Van Soest EM, Sturkenboom MC, Dieleman JP, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007; 26: 265–75PubMedCrossRefGoogle Scholar
  129. 129.
    Abraham NS, Hartman C, Castillo D, et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol 2008; 103: 323–32PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Department of GastroenterologyL. Sacco University HospitalMilanItaly

Personalised recommendations